Engineered biologics win FDA nod, opening doors across the blood–brain barrier
The first FDA-approved engineered biologic that can cross the blood–brain barrier marks a milestone in CNS drug delivery, as researchers accelerate brain-shuttle approaches to ferry large-molecule therapies into the brain for potential treatments of neurological diseases.